{
  "directed": true,
  "graph": {
    "annotation_list": {
      "MeasurementRelation": [
        "=",
        "~"
      ],
      "MeasurementType": [
        "CSF concentration",
        "IC50",
        "brain concertration",
        "dose",
        "plasma concentration"
      ],
      "MeasurementUnits": [
        "mg",
        "μM"
      ]
    },
    "annotation_pattern": {
      "ArticleCompoundNumber": ".*",
      "Figure": ".*",
      "MeasurementRangeLower": ".*",
      "MeasurementRangeUpper": ".*",
      "MeasurementValue": ".*",
      "Page": ".*",
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "document_metadata": {
      "authors": "Lingling Xu",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-b peptide and s levels: target engagement, tolerability and pharmacokinetics in humans",
      "version": "0.1.0"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "PUBCHEM": "^\\d+$",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/501ceccdc9a27d97edbdc48a89ebe8e1dd3626e9/export/conso-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"
    },
    "path": "app/maccecchini2012.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "1": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "2A": true
        },
        "MeasurementType": {
          "dose": true
        },
        "MeasurementUnits": {
          "mg": true
        },
        "MeasurementValue": {
          "160": true
        },
        "Page": {
          "896": true
        }
      },
      "citation": {
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "db": "PubMed",
        "db_id": "22791904",
        "db_name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "first": "Maccecchini ML",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "A 160 mg dose was associated with an increased incidence of nausea and vomiting (four subjects were nauseous and three vomited)",
      "key": "a3f08b819a615074a05f85f641063480",
      "line": 96,
      "relation": "increases",
      "source": 0,
      "target": 9
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "1": true
        },
        "Confidence": {
          "High": true
        },
        "MeasurementType": {
          "dose": true
        },
        "MeasurementUnits": {
          "mg": true
        },
        "MeasurementValue": {
          "80": true
        },
        "Page": {
          "896": true
        }
      },
      "citation": {
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "db": "PubMed",
        "db_id": "22791904",
        "db_name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "first": "Maccecchini ML",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "Posiphen 80 mg was determined as the no observed adverse effect level (table 1).",
      "key": "c400807a73c04082183e657ba22412ba",
      "line": 109,
      "relation": "causesNoChange",
      "source": 0,
      "target": 9
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "1": true
        },
        "Confidence": {
          "High": true
        },
        "Figure": {
          "2A": true
        },
        "MeasurementType": {
          "dose": true
        },
        "MeasurementUnits": {
          "mg": true
        },
        "MeasurementValue": {
          "160": true
        },
        "Page": {
          "896": true
        }
      },
      "citation": {
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "db": "PubMed",
        "db_id": "22791904",
        "db_name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "first": "Maccecchini ML",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "A 160 mg dose was associated with an increased incidence of nausea and vomiting (four subjects were nauseous and three vomited)",
      "key": "75a66d730d1e3479b4f34ede98243e98",
      "line": 97,
      "relation": "increases",
      "source": 0,
      "target": 10
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "1": true
        },
        "Confidence": {
          "High": true
        },
        "MeasurementType": {
          "dose": true
        },
        "MeasurementUnits": {
          "mg": true
        },
        "MeasurementValue": {
          "80": true
        },
        "Page": {
          "896": true
        }
      },
      "citation": {
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "db": "PubMed",
        "db_id": "22791904",
        "db_name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "first": "Maccecchini ML",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "Posiphen 80 mg was determined as the no observed adverse effect level (table 1).",
      "key": "29afed9a085ac828f7205000023f6909",
      "line": 110,
      "relation": "causesNoChange",
      "source": 0,
      "target": 10
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "1": true
        },
        "Confidence": {
          "High": true
        },
        "Page": {
          "899": true
        }
      },
      "citation": {
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "db": "PubMed",
        "db_id": "22791904",
        "db_name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "first": "Maccecchini ML",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "Specifically, Posiphen lowered sAPPa and sAPPb levels by \u000159.9% and \u000157.7%, respectively, assessed by the AlpaLisa assay, and by \u000134.1% and \u000134%, respectively, assessed by the MSD assay, in accordance with Posiphen’s proposed mechanism of action to inhibit APP expression.",
      "key": "b6542104f3c5f7445ece701923ef8838",
      "line": 118,
      "relation": "decreases",
      "source": 0,
      "target": 1
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "1": true
        },
        "Confidence": {
          "High": true
        },
        "Page": {
          "899": true
        }
      },
      "citation": {
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "db": "PubMed",
        "db_id": "22791904",
        "db_name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "first": "Maccecchini ML",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "Specifically, Posiphen lowered sAPPa and sAPPb levels by \u000159.9% and \u000157.7%, respectively, assessed by the AlpaLisa assay, and by \u000134.1% and \u000134%, respectively, assessed by the MSD assay, in accordance with Posiphen’s proposed mechanism of action to inhibit APP expression.",
      "key": "7f12dabe70a531bd4dbe3aa42298a210",
      "line": 119,
      "relation": "decreases",
      "source": 0,
      "target": 2
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "1": true
        },
        "Confidence": {
          "High": true
        },
        "Page": {
          "899": true
        }
      },
      "citation": {
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "db": "PubMed",
        "db_id": "22791904",
        "db_name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "first": "Maccecchini ML",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "In addition, Posiphen significantly reduced levels of t-s (\u000174.1%, as assessed by the Innogenetics assay and \u000146.2%, as assessed by the AlphaLisa assay) and p-s (\u000161%, as assessed by the Innogenetics assay).",
      "key": "7f4adc335092c26ac32de319ef1bcbb7",
      "line": 124,
      "relation": "decreases",
      "source": 0,
      "target": 7
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "1": true
        },
        "Confidence": {
          "High": true
        },
        "Page": {
          "899": true
        }
      },
      "citation": {
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "db": "PubMed",
        "db_id": "22791904",
        "db_name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "first": "Maccecchini ML",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "In addition, Posiphen significantly reduced levels of t-s (\u000174.1%, as assessed by the Innogenetics assay and \u000146.2%, as assessed by the AlphaLisa assay) and p-s (\u000161%, as assessed by the Innogenetics assay).",
      "key": "7c074d4650e075802351524884a6b12f",
      "line": 125,
      "relation": "decreases",
      "source": 0,
      "target": 8
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "1": true
        },
        "Confidence": {
          "High": true
        },
        "Page": {
          "899": true
        }
      },
      "citation": {
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "db": "PubMed",
        "db_id": "22791904",
        "db_name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "first": "Maccecchini ML",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": " A significant lowering of pro-inflammatory, C3 (\u000186.9%) and microglial activation markers, MCP-1 (\u000187.5%) and YKL-40 (\u000172.7%), was evident.",
      "key": "c2a978c23e93e0051d7b4f271359117b",
      "line": 130,
      "relation": "decreases",
      "source": 0,
      "target": 3
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "1": true
        },
        "Confidence": {
          "High": true
        },
        "Page": {
          "899": true
        }
      },
      "citation": {
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "db": "PubMed",
        "db_id": "22791904",
        "db_name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "first": "Maccecchini ML",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": " A significant lowering of pro-inflammatory, C3 (\u000186.9%) and microglial activation markers, MCP-1 (\u000187.5%) and YKL-40 (\u000172.7%), was evident.",
      "key": "723e15845187de4ebef1a6687a208fc7",
      "line": 131,
      "relation": "decreases",
      "source": 0,
      "target": 4
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "1": true
        },
        "Confidence": {
          "High": true
        },
        "Page": {
          "899": true
        }
      },
      "citation": {
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "db": "PubMed",
        "db_id": "22791904",
        "db_name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "first": "Maccecchini ML",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": " A significant lowering of pro-inflammatory, C3 (\u000186.9%) and microglial activation markers, MCP-1 (\u000187.5%) and YKL-40 (\u000172.7%), was evident.",
      "key": "768ad852ee23d3d1a403d22f1b13dd67",
      "line": 132,
      "relation": "decreases",
      "source": 0,
      "target": 6
    },
    {
      "annotations": {
        "ArticleCompoundNumber": {
          "1": true
        },
        "Confidence": {
          "High": true
        },
        "Page": {
          "899": true
        }
      },
      "citation": {
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "db": "PubMed",
        "db_id": "22791904",
        "db_name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "first": "Maccecchini ML",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "and the complement control protein, factor H, were unaffected by Posiphen (\u000126.1% and +23.7%, respectively).",
      "key": "b72b181343d99b8d93966211d9d08799",
      "line": 137,
      "relation": "causesNoChange",
      "source": 0,
      "target": 5
    },
    {
      "key": "064f60bbd4e86ec0d71e89e733af2e71",
      "relation": "hasVariant",
      "source": 7,
      "target": 8
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(PUBCHEM:11249342)",
      "concept": {
        "name": "11249342",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "0a63bb4c27cfcfd8a51a997280b57bac"
    },
    {
      "bel": "p(CONSO:\"sAPP-alpha\")",
      "concept": {
        "name": "sAPP-alpha",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "8846a5456d7a07582369bbaed50c87d7"
    },
    {
      "bel": "p(CONSO:\"sAPP-beta\")",
      "concept": {
        "name": "sAPP-beta",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "6b57d0f32e7301273a36c1e13f0d25d7"
    },
    {
      "bel": "p(HGNC:C3)",
      "concept": {
        "name": "C3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "26a8a2f1cb63e49c899e482f0bcf01f3"
    },
    {
      "bel": "p(HGNC:CCL2)",
      "concept": {
        "name": "CCL2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "2a1fddd8526478c2c7edadaa639bbe85"
    },
    {
      "bel": "p(HGNC:CFH)",
      "concept": {
        "name": "CFH",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "afb9aa5abfd9d2c6fd6d71af95794009"
    },
    {
      "bel": "p(HGNC:CHI3L1)",
      "concept": {
        "name": "CHI3L1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "17cc90471d0859ee3991ac6970983309"
    },
    {
      "bel": "p(HGNC:MAPT)",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7d1009217050e75d549c8c5aa83309a8"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "a8fb3a87d5a0672c07462bb17c8b0947",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "path(MESH:Nausea)",
      "concept": {
        "name": "Nausea",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "41e2b9e6454d4c63a3654236ce97040f"
    },
    {
      "bel": "path(MESH:Vomiting)",
      "concept": {
        "name": "Vomiting",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "364ae88ab20bb2e8a9fd696110a8f558"
    }
  ]
}